India Glycols Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2025, recommended Final Dividend of Rs. 10 per equity share.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.7 pts less than its Breweries & Distilleries peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
India Glycols' board, at its May 16, 2025 meeting, approved audited standalone and consolidated results for Q4 and FY25 with an unmodified auditor's opinion. Standalone revenue rose 14% year-on-year to Rs. 9,037.82 Cr, while profit after tax grew nearly 19% to Rs. 180.38 Cr. Consolidated profit after tax jumped about 33% to Rs. 230.92 Cr, helped by a stronger contribution from the Clariant IGL joint venture. The board recommended a final dividend of Rs. 10 per share (100% on face value) subject to shareholder approval. The company also confirmed it will now pursue only the demerger of its Bio Pharma and Spirits & Biofuel businesses into separate listed entities, dropping the earlier plan to merge Kashipur Holdings; the scheme's appointed date is April 1, 2026.
Shareholders stand to receive a healthy Rs. 10 per share dividend along with strong profit growth, especially on a consolidated basis. The simplification of the restructuring to a pure demerger could unlock value more clearly by separating the high-growth Bio-Fuel and stable Spirits businesses, though it remains subject to NCLT and shareholder approvals.